TauRx' anti-tau could be safer disease-modifying therapy for Alzheimer's

11 October 2022

Singapore-based TauRx Pharmaceuticals, a company that claims to be the global leader in tau-based research in Alzheimer’s disease, recently reported positive progress for the firm's lead investigative oral drug hydromethylthionine mesylate (HMTM). The drug was found to be effective in improving cognition in patients with early Alzheimer’s disease (AD).

TauRx now plans to submit HMTM for regulatory approval in the USA and Canada in 2023, with other territories to follow, in line with its overall plans to commercialize HMTM and pursue clinical trials in other related neurodegenerative diseases.

Reviewing the situation, pharma analytic firm GlobalData’s senior neurology analyst Pippa Salter said: “A key unmet need in the AD market is for the development of disease-modifying therapies (DMTs) that can stop or even reverse the disease. Historically, the amyloid hypothesis has dominated the AD space, however, with multiple failures of amyloid-targeting drug candidates, the focus has widened to include anti-tau therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK